We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Venn Life Sciences Holdings Plc | LSE:VENN | London | Ordinary Share | GB00B9275X97 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 6.85 | 6.70 | 7.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMORPH
RNS Number : 0602A
AIM
16 January 2020
ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION IN ACCORDANCE WITH RULE 2 OF THE AIM RULES FOR COMPANIES ("AIM RULES") COMPANY NAME: Open Orphan plc COMPANY REGISTERED OFFICE ADDRESS AND IF DIFFERENT, COMPANY TRADING ADDRESS (INCLUDING POSTCODES) : Registered Office: PO Box W1J 6BD, Berkley Square House, 2nd Floor, Mayfair, London, W1J 8DJ Trading Offices: 19 Railway Road, Dalkey, Dublin, Ireland Queen Mary BioEnterprises (QMB) Innovation Centre, 42 New Road, London, E1 2AX COUNTRY OF INCORPORATION: England and Wales COMPANY WEBSITE ADDRESS CONTAINING ALL INFORMATION REQUIRED BY AIM RULE 26: www.openorphan.com COMPANY BUSINESS (INCLUDING MAIN COUNTRY OF OPERATION) OR, IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS INVESTING POLICY). IF THE ADMISSION IS SOUGHT AS A RESULT OF A REVERSE TAKE-OVER UNDER RULE 14, THIS SHOULD BE STATED: This is a reverse takeover under Rule 14. Open Orphan is a Clinical Research Organisation that specialises in rare and orphan drugs. The headquarters are in Dublin, Ireland and the company also has offices in the UK, France, the Netherlands and Germany. DETAILS OF SECURITIES TO BE ADMITTED INCLUDING ANY RESTRICTIONS AS TO TRANSFER OF THE SECURITIES (i.e. where known, number and type of shares, nominal value and issue price to which it seeks admission and the number and type to be held as treasury shares): Number of ordinary shares of 0.1 pence each in nominal value ("Ordinary Shares") for which Admission will be sought: 445,622,374 There are no restrictions as to the transferability of the Ordinary Shares and no Ordinary Shares will be held in treasury. CAPITAL TO BE RAISED ON ADMISSION (AND/OR SECONDARY OFFERING) AND ANTICIPATED MARKET CAPITALISATION ON ADMISSION: Expected Market Capitalisation: GBP29.6 million (based on an enlarged share capital of 445,622,374 and closing price per Open Orphan Shares of GBP0.0665 on 15 January 2020) No capital to be raised on admission PERCENTAGE OF AIM SECURITIES NOT IN PUBLIC HANDS AT ADMISSION: 22.8% DETAILS OF ANY OTHER EXCHANGE OR TRADING PLATFORM TO WHICH THE AIM SECURITIES (OR OTHER SECURITIES OF THE COMPANY) ARE OR WILL BE ADMITTED OR TRADED: Euronext Growth FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS (underlining the first name by which each is known or including any other name by which each is known): Directors Cathal Friel, Executive Chairman Brendan Buckley, Non-executive Director Proposed Directors Dr Trevor Phillips, Chief Executive Officer Dr Mark Warne, Non-executive Director Michael Meade, Non-executive Director FULL NAMES AND HOLDINGS OF SIGNIFICANT SHAREHOLDERS EXPRESSED AS A PERCENTAGE OF THE ISSUED SHARE CAPITAL, BEFORE AND AFTER ADMISSION (underlining the first name by which each is known or including any other name by which each is known): Before Admission: Name Number of Ordinary Percentage of issued Shares share capital Cathal Friel 41,046,981 16.1% ------------------- --------------------- Anthony (Tony) Richardson 16,313,388 6.4% ------------------- --------------------- Gresham House Asset Management 13,081,337 5.1% ------------------- --------------------- Crux Asset Management 11,928,571 4.7% ------------------- --------------------- Brendan Buckley 7,845,860 3.1% ------------------- --------------------- After Admission: Name Number of Ordinary Percentage of issued Shares share capital Cathal Friel 41,046,981 9.2% ------------------- --------------------- Anthony (Tony) Richardson 16,313,388 3.7% ------------------- --------------------- Gresham House Asset Management 13,081,337 2.9% ------------------- --------------------- Crux Asset Management 11,928,571 2.7% ------------------- --------------------- Brendan Buckley 7,845,860 1.8% ------------------- --------------------- Invesco Ltd 52,485,973 11.8% ------------------- --------------------- Link Fund Solutions Ltd 38,618,608 8.7% ------------------- --------------------- IP Group plc 32,267,791 7.2% ------------------- --------------------- Jupiter Asset Management Ltd 22,819,579 5.1% ------------------- --------------------- NAMES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 2, PARAGRAPH (H) OF THE AIM RULES: n/a (i) ANTICIPATED ACCOUNTING REFERENCE DATE (ii) DATE TO WHICH THE MAIN FINANCIAL INFORMATION IN THE ADMISSION DOCUMENT HAS BEEN PREPARED (this may be represented by unaudited interim financial information) (iii) DATES BY WHICH IT MUST PUBLISH ITS FIRST THREE REPORTS PURSUANT TO AIM RULES 18 AND 19: (i) 31 December (ii) 31 December 2019 (iii) 31 December 2019 due 30 June 2020, 30 June 2020 due September 2020, 31 December 2020 due 30 June 2021 EXPECTED ADMISSION DATE: 20 January 2020 NAME AND ADDRESS OF NOMINATED ADVISER: Arden Partners plc 125 Old Broad Street London EC2N 1AR NAME AND ADDRESS OF BROKER: Arden Partners plc 125 Old Broad Street London EC2N 1AR OTHER THAN IN THE CASE OF A QUOTED APPLICANT, DETAILS OF WHERE (POSTAL OR INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL BE AVAILABLE FROM, WITH A STATEMENT THAT THIS WILL CONTAIN FULL DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITS SECURITIES: A copy of the admission document containing full details about the applicant and the admission of its securities is available on the Company's website, www.openorphan.com THE CORPORATE GOVERNANCE CODE THE APPLICANT HAS DECIDED TO APPLY The QCA Corporate Governance Code 2018 published by the Quoted Companies Alliance DATE OF NOTIFICATION: 16 January 2020 NEW/ UPDATE: UPDATE
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
AIMUNRURRKUAAAR
(END) Dow Jones Newswires
January 16, 2020 09:00 ET (14:00 GMT)
1 Year Venn Life Sciences Chart |
1 Month Venn Life Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions